Haiyi Jiang, M.D.
AstraZeneca · Zhangjiang Hi-tech Park, 3F, Room 3102, 199 Liangjing Road, Pudong Shanghai, postal code:201203
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Haiyi Jiang, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:08 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT03703297 · Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyAstraZeneca · active not recruiting · Small Cell Lung Cancer · study director
- Ph3NCT03043872 · Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)AstraZeneca · active not recruiting · Small Cell Lung Carcinoma Extensive Disease · study director
- Ph2NCT02937818 · A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung CancerAstraZeneca · completed · Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma · study director
- Ph3NCT01544179 · A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy AloneAstraZeneca · completed · Non-Small Cell Lung Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.